Literature DB >> 32219874

Reverse transcriptase droplet digital PCR versus reverse transcriptase quantitative real-time PCR for serum HBV RNA quantification.

Umaporn Limothai1, Natthaya Chuaypen1, Kittiyod Poovorawan2, Watcharasak Chotiyaputta3, Tawesak Tanwandee3, Yong Poovorawan4, Pisit Tangkijvanich1.   

Abstract

Serum hepatitis B virus (HBV) RNA is a novel marker reflecting the activity of covalently closed circular DNA. However, the methodology for detecting HBV RNA has been a technical challenge. In this study, the performance of reverse transcription droplet digital PCR (RT-ddPCR) for quantifying HBV RNA was compared with that of reverse transcription quantitative real-time PCR (RT-qPCR) in serum samples collected from treatment-naïve patients with different phases of chronic hepatitis B (CHB). A total of 417 serum samples, including 136 HBeAg-positive CHB and 281 HBeAg-negative CHB were examined. HBV RNA levels measured by RT-ddPCR and RT-qPCR showed a high degree of linearity and quantitative correlation. The limit of detections of RT-ddPCR and RT-qPCR assays were 102 and 103 copies/mL, respectively. Our results also demonstrated that RT-ddPCR was superior to RT-qPCR in terms of its consistency for quantifying HBV RNA across all concentrations. In the HBeAg-positive group, serum HBV RNA levels based on RT-ddPCR were moderately correlated with HBV DNA (r=0.591, P<0.001) and HBsAg (r=0.502, P<0.001). Among patients with HBeAg-negative CHB, serum HBV RNA levels were moderately correlated with HBV DNA (r=0.603, P<0.001) but had weak correlation with HBsAg (r=0.203, P=0.001). In summary, RT-ddPCR could enhance the sensitivity of serum HBV RNA detection, particularly among the HBeAg-negative group with low viral loads. Thus, RT-ddPCR could serve as an optimal method for HBV RNA quantification in clinical practice. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.

Entities:  

Keywords:  Serum HBV RNA; chronic hepatitis B; droplet digital PCR; quantitative real-time PCR

Year:  2020        PMID: 32219874     DOI: 10.1002/jmv.25792

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  4 in total

Review 1.  A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook.

Authors:  Anna Kramvis; Kyong-Mi Chang; Maura Dandri; Patrizia Farci; Dieter Glebe; Jianming Hu; Harry L A Janssen; Daryl T Y Lau; Capucine Penicaud; Teresa Pollicino; Barbara Testoni; Florian Van Bömmel; Ourania Andrisani; Maria Beumont-Mauviel; Timothy M Block; Henry L Y Chan; Gavin A Cloherty; William E Delaney; Anna Maria Geretti; Adam Gehring; Kathy Jackson; Oliver Lenz; Mala K Maini; Veronica Miller; Ulrike Protzer; Jenny C Yang; Man-Fung Yuen; Fabien Zoulim; Peter A Revill
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-07-20       Impact factor: 73.082

Review 2.  Droplet digital PCR of viral ‎DNA/RNA, current progress, challenges, and future perspectives.

Authors:  Amir Asri Kojabad; Mahdieh Farzanehpour; Hadi Esmaeili Gouvarchin Galeh; Ruhollah Dorostkar; Ali Jafarpour; Masoumeh Bolandian; Majid Mirzaei Nodooshan
Journal:  J Med Virol       Date:  2021-03-11       Impact factor: 20.693

3.  Clinical Utility of SCALE-B to Predict Hepatitis B Virus Relapse, Hepatitis B Surface Antigen Loss After Antiviral Cessation in Asian Patients After 2-Year Follow-up.

Authors:  Apichat Kaewdech; Suraphon Assawasuwannakit; Pimsiri Sripongpun; Naichaya Chamroonkul; Pisit Tangkijvanich; Teerha Piratvisuth
Journal:  Front Med (Lausanne)       Date:  2022-03-24

Review 4.  Novel Biomarkers of Hepatitis B Virus and Their Use in Chronic Hepatitis B Patient Management.

Authors:  Alicia Vachon; Carla Osiowy
Journal:  Viruses       Date:  2021-05-21       Impact factor: 5.048

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.